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Summary 
L-selectin mediates leukocyte rolling on vascular endothelium at sites of inflammation and lym- 
phocyte migration to peripheral lymph nodes. L-selectin  is rapidly shed from the cell surface 
after leukocyte activation by a proteolytic mechanism that cleaves the receptor in a membrane 
proximal extracellular  region. This process  may allow rapid leukocyte detachment from the 
endothelial surface before entry into tissues. In this study, the structural requirements for regulation 
of human L-selectin endoproteolytic release were examined through analysis of chimeric selectin 
molecules and mutant L-selectin receptors.  The use of chimeric selectins and a cytoplasmic tail 
truncation mutant demonstrated that the extracellular membrane-proximal 15-amino acid region 
of L-selectin is required for endoproteolytic  release. The introduction of alanine-scanning mutations 
within this membrane-proximal region did not prevent endoproteolytic release, indicating that 
a specific amino acid motif was not an absolute requirement for cleavage. Furthermore, alterations 
within the putative primary cleavage site (K283-$284) resulted in either constitutive endoproteo- 
lyric release of the receptor or inhibition of cell activation-induced shedding to variable extents. 
The length of the membrane-proximal region was also critical  since truncations of this region 
completely abolished endoproteolytic release. Thus, release of L-selectin is likely to be regulated 
by the generation of an appropriate tertiary conformation within the membrane-proximal region 
of the receptor which allows recognition by a membrane-bound endoprotease with relaxed sequence 
specificity  that cleaves the receptor at  a specific distance  from the plasma membrane. These 
observations suggest a generalized protein-processing pathway involved in the endoproteolytic 
release of specific transmembrane proteins which harbor widely differing primary sequences at 
or neighboring their cleavage sites. 
C 
ell function can be directly controlled by increasing or 
decreasing cell-surface receptor expression.  While sur- 
face receptor expression can be regulated by a variety of mech- 
anisms, three mechanisms predominantly account for the rapid 
down-regulation of cell surface receptors: internalization, en- 
doproteolytic release of transmembrane proteins, and glycolipid 
cleavage of glycosylphosphatidylinositol-anchored  proteins. 
In addition to down-regulation of receptor expression,  en- 
doproteolytic release often generates a soluble protein that 
retains receptor function (1, 2). Examples of shed receptors 
include growth factor receptors such as the receptors for IL-1, 
IL-2, insulin, growth hormone, TNF (3), CSF-1 (4), epider- 
mal growth factor, and nerve growth factor (5). Also included 
in this list are several immunologically important receptors, 
including L-selectin (CD62L) (6-12), CD14, CD43, CD44, 
FceRII (CD23), FcqcRII (CD32), and FcqcRIII (CD16). In 
addition, the/3 amyloid precursor protein which has been 
implicated in the genesis of Alzheimer's disease is proteolyti- 
cally shed from the cell surface giving rise to amyloid 3 pep- 
tide (13). These proteins are quite diverse in structure and 
amino acid sequence and have few unifying functional char- 
acteristics (1, 2). However, only a small fraction of all cell- 
surface receptors are released from the cell surface. The pre- 
cise substrate specificities and the mechanisms that regulate 
the membrane-bound endoprotease(s) that mediate in situ 
cleavage of these receptors have not been completely elucidated. 
L-selectin is normally expressed on the surface of most leu- 
kocytes, induding lymphocytes, neutrophils, monocytes, eo- 
sinophils,  hematopoietic progenitor  cells, and  immature 
thymocytes (7, 11, 14, 15). L-selectin mediates the binding 
of lymphocytes to high endothelial venules (HEV) 1 of pe- 
ripheral lymph nodes (7, 9,  12, 14), and is also involved in 
leukocyte attachment to endothelium at sites of inflamma- 
1 Abbreviations used in this paper: CHO, Chinese  hamster ovary; EGF, 
epidermal growth factor; HEV, high endothelial  venules; SCR, short 
consensus repeat; sL-selectin, shed L-selectin. 
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Volume 182  August 1995  519-530 tion (16-22).  Leukocytes from mice lacking L-selectin are 
deficient in both activities (23-25).  Human L-selectin is a 
highly glycosylated protein of 95-105,000  Mr on neutrophils 
and 74,000  on lymphocytes (11, 12, 26). L-selectin is rapidly 
shed from the cell surface  after cellular activation in vitro 
or after exposure to the nonphysiologic stimulator phorbol 
esters (PMA) (6-9, 11, 12). In addition, shedding also occurs 
during overnight incubation of  lymphocytes  at 4~  and during 
cell culture (27-29).  It has been proposed that endoproteo- 
lytic release of L-selectin might provide a rapid means for 
the regulation of leukocyte deadhesion necessary  to enable 
leukocytes to detach from bound endothelial cells before trans- 
migration between endothelial cells and into sites of inflam- 
mation (6,  17). However, the protease(s)  that mediate en- 
doproteolytic  release  of L-selectin  appear  ubiquitous,  as 
opposed to cell type-specific, since a broad array of L-selec- 
tin-negative cell types tranfected with L-selectin cDNA are 
able to shed this receptor (9, 28-31).  Shed L-selectin (sL-selec- 
tin) is found in normal plasma at high levels ('~1-3 #g/m1) 
and retains functional activity (28,  29,  32, 33).  Thus,  the 
endoproteolytic release of L-selectin may not only be a means 
of regulating cell-surface  receptor expression, but the shed 
receptor may also modulate leukocyte binding to endothelium 
in vivo. 
The selectins have a unique and characteristic domain struc- 
ture that includes an extracellular C-type lectin domain, a 
single epidermal growth factor (EGF)-like domain, and be- 
tween two and nine short consensus repeat (SCR) units ho- 
mologous to domains found in complement-binding proteins 
(30,  34-37). The three selectins  (L-, E-, and P-selectin)  are 
closely related to each other in amino acid sequence, ranging 
from ,,o40%  identity in the SCR domains up to ,'065%  in 
the lectin and EGF-like domains (15). Although the amino 
acid sequences of the membrane-proximal region, transmem- 
brane region, and cytoplasmic tail of L-selectin from various 
mammalian species are very well conserved, the three selectins 
are quite divergent in these regions (Fig.  1). It is likely that 
endoproteolytic release of L-selectin results from cleavage of 
L-selectin in the membrane-proximal region of the transmem- 
brane domain, since sL-selectin  is 5-6,000  less in Mr than 
cell-surface L-selectin (6, 8, 9, 30).  In fact, one study using 
radiochemical sequencing has  suggested that the protease 
cleavage site in L-selectin is the peptide bond between K 283 
and S  TM  in the membrane-proximal region (31). However, 
the proposed  recognition motif K283SFS is  not well con- 
served in bovine L-selectin, while this receptor is also shed 
(38,  39).  While soluble E- and P-selectin are also found in 
normal plasma,  they are  at levels significantly lower than 
L-selectin (32,  40, 41). However, soluble P-selectin  is pro- 
posed to be generated by alternative splicing of the mRNA 
transcript with deletion of the transmembrane domain (36). 
Nonetheless,  differences  between  the membrane-proximal 
regions of the selectins may explain why L-selectin is proteo- 
lyrically  cleaved from the cell surface at such a rapid rate after 
cellular activation in contrast to E- and P-selectin. 
Understanding the mechanism for regulation of L-selectin 
endoproteolytic release will be important for understanding 
how this event may regulate leukocyte migration. Blocking 
endoproteolytic release may also provide a way to inhibit the 
accumulation of leukocytes at sites of inflammation. In addi- 
tion, L-selectin also serves as an excellent model system for 
understanding  the  more  general  process  of receptor  en- 
doproteolytic cleavage. In this report, the amino acid sequence 
requirements for L-selectin endoproteolytic release were ex- 
amined using chimeric receptors,  truncation mutants, and 
site-specific mutants. The results revealed a primary proteo- 
lytic activity with a relaxed sequence  specificity dependent 
on  an  appropriate  conformation  within  the  membrane- 
proximal region of L-selectin.  This  functional activity is 
remarkably similar to that of the structurally undefined en- 
doprotease, ce-secretase, which mediates the conventional secre- 
tory processing of 3-amyloid precursor protein, a cell-surface 
molecule involved in Alzheimer's disease (13). This suggests 
that these two proteins and others may be cleaved by a similar, 
if not  identical,  widely distributed membrane-bound en- 
doprotease. 
Materials and Methods 
Construction of Chimeric and Mutant Selectin cDNA.  Chimeric 
L- and P-selectin eDNA (P4L and L4P, Fig. 2 A) were constructed 
as described (42). The LAcyto (Figs. 1 and 2 A) mutant receptor 
was generated as described (43). Site-specific  mutations and dele- 
tions in the membrane-proximal region were introduced by stan- 
dard PCR mutagenesis protocols or two-step recombinant PCR 
procedures. The K283A and KE mutant receptors (Fig. 2 B) were 
generated using two "inner" complementary PCR primers syn- 
thesized based on the membrane-proximal  region sequence. These 
primers introduced new amino acid residues and unique restriction 
sites. Individual "outer" primers that were complementary to ei- 
ther sequences at the upstream KpnI or downstream NdeI sites 
were used with individual inner primers to generate DNA frag- 
ments using L-selectin eDNA in pSP65 as template for the first 
PCR reaction. The two resulting PCR products were hybridized 
together and used as templates for the second PCR reaction which 
used only the two outer primers. These products were digested 
with KpnI/NdeI and cloned into the Kpnl and NdeI sites of  L-selec- 
tin cDNA in pSP65. The KE mutant eDNA had a SacII site at 
the mutation site so it was used as a PCR template to make other 
alanine-scanning mutants within the membrane-proximal region 
(Fig. 2 A). One PCR primer containing the necessary mutation 
for each new receptor was synthesized based on the membrane- 
proximal region sequence of the KE mutant eDNA. This primer 
was paired with one of the two outer primers described earlier for 
PCR amplification.  The resulting PCR products were digested  with 
KpnI/SaclI or SacII/NdeI and subcloned into the corresponding 
sites within the KE mutant eDNA in pSP65. The resulting mu- 
tant receptors therefore had alanine substitutions at KE  29~ in ad- 
dition to the newly introduced mutations. Both the KLD.KE and 
KEGDYN mutants had an introduced NotI site at the mutation 
sites. Thereby, joining the appropriate EcoRI/NotI fragment of 
the KLD.KE and KEGDYN mutants generated a mutant in which 
the membrane-proximal  region was replaced  by AAAG. This AAAG 
mutant cDNA served as a template for generation of the AK-S 
and AM-N deletion mutants in a similar  manner as described above 
using two complementary inner primers containing sequences en- 
coding either MIKEGDYN or KLDKSFS.  All of the chimeric and 
mutant eDNA were subcloned into pSP65 and were verified by 
sequence determination. 
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Figure  1.  Amino acid sequence alignments of the membrane proximal and transmembrane regions of human (34), mouse (30), rat (37a), and bovine 
(38) bselectin,  human P-sdectin (36), and human E-selectin (37). Amino acid positions for the mature human L-selectin  protein are indicated above 
the sequence. The amino acid sequence for the bovine L-sdectin cytoplasmic domain is not as published since an amino acid sequence that is optimal 
for alignment with L-selectin  from other species is generated when it is assumed that an extra nucleotide was inserted between nudeotides  1214 and 
1220 as published (38). The membrane-proximal region of the transmembrane domain of the selectins is boxed and the putative membrane-spanning 
regions are underlined. Dashes indicate amino acids identical to those found in human bselectin with spaces introduced to generate optimal alignment. 
The Asn  273 indicated by a # is the crossover point for the L4P chimeric selectin and the Gly  323 indicated by a # is the truncation  point for LAcyto 
mutant receptor. Only a portion of the cytoplasmic domains of E- and P-sdectin are shown as indicated by (...). The putative endopeptidase cleavage 
site is indicated by an arrow. 
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Figure 2.  Structure and amino acid sequences of chimeric selectins  and 
mutant L-sdectin  molecules.  (.4) Schematic  structure of bsdectin, P-selectin, 
and chimeric receptors. Only two of the nine SCR present in P-selectin 
are represented. The membrane spanning region of the transmembrane 
domain (TM) is shown in black which proceeds the cytoplasmic (C) do- 
main. (B) Mutations in the membrane-proximal region of the transmem- 
brane domain are shown with altered amino acids underlined. Deleted 
amino acids are indicated by a dash. 
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Generation of Cell Lines Expressing Chimeric and Mutant Recep- 
tors.  cDNA encoding native L-selectin, L4P, and the membrane- 
proximal region mutants were subcloned into the pMT2 expres- 
sion vector and, along with the pSV2neo vector containing the 
neomycin resistance marker, were used to cotransfect the mouse 
pre-B cell line 300.19 (44). LAcyto cDNA was subcloned into the 
pZIPneoSV vector and used to transfect 300.19  cells as reported 
(43).  Stable transfectants of 300.19  cells were selected in medium 
containing 1.0 mg/ml G418 (geneticin; Sigma Chemical Co., St. 
Louis, MO). 20 clones from each transfection were examined by 
indirect immunofluorescence screening for bselectin expression. 
The clones with the highest levels of expression were used in these 
studies. A  done of Chinese hamster ovary cells transfected with 
the P4L cDNA (termed PPP) was generated as described (45) and 
was generously provided by Dr. Bruce Furie (New England Med- 
ical Center, Boston, MA). 
Antibodies.  bselectin mAbs were anti-LAM1-3 directed against 
an epitope within the lectin domain, anti-LAMl-1 identifying the 
EGF-like domain, and anti-LAM1-14 which reacts with SCP,, all 
of the IgGa isotype (46).  Anti-bselectin mAbs were purified by 
salt fractionation followed by anion exchange chromatography, with 
the mAb concentration determined by light absorption. Purified 
mAbs were used for ELISA and ascites fluid diluted to the optimal 
concentration was used for indirect immunofluorescence staining. 
The AC1.2 mAb reactive with P-selectin was generously provided 
by Dr.  Bruce Furie. 
Cell Cultures and Induction of Endoproteolytic Release.  300.19 cells 
were cultured in P,  PMI 1640 medium containing 10% FCS, 2% 
L-glutamine,  penicillin,  streptomycin,  and  2-mercaptoethanol. 
CHO-P4L cells were cultured in ~ MEM medium containing 10% 
FCS, 2% r-glutamine, penicillin, and streptomycin. All ceils were 
incubated at 37~  in 5% COs with 100%  humidity. To induce 
endoproteolytic release for cell-surface analysis,  ,~0.5  x  106 cells 
were cultured in 0.4 ml of medium containing 50 ng/ml PMA 
in a test tube at 37~  for 30 min before analysis.  To induce en- 
doproteolytic release for ELISA analysis, ,'~2  x  106 cells were cul- 
tured in 0.4 ml of medium containing 50 ng/ml PMA in a test tube at 37~  for 30 min.  After centrifugation,  the supernatant 
was saved and the pellet was lysed  at 4~  for 30 rain in 0.4 ml 
of lysis buffer (50 mM Tris-HC1, 0.5%  NP-40,  150 mM NaC1, 
0.1%  BSA,  5 mM EDTA,  1 mM PMSF,  pH 7.5).  For studying 
spontaneous endoproteolytic release, ,,~2 x  106 cells were washed 
and cultured for 24 h in 10 ml of culture medium. Aliquots (1.5 
ml) of the cell suspension were centrifuged and the supernatant 
and the cell pellet lysed as described above were used for ELISA 
analysis. 
Indirect Immunofluorescence Analysis.  Indirect immunofluores- 
cence analysis was carried out after washing the cells three times. 
Cells (0.5  x  106) were resuspended in 100 gl of media containing 
optimal concentrations of mAb, and incubated for 30 min at 4~ 
After washing, the cells were treated with FITC-conjugated goat 
anti-mouse Ig antibodies (Southern Biotechnology Associates, Bir- 
mingham, AL) for 20 min at 4~  The cells were washed,  and 
fixed (1.5% formalin in PBS),  and single-color fluorescence anal- 
ysis was carried out by flow cytometry (ELITET~; Coulter Im- 
munology, Hialeah, FL). 10,000 cells were analyzed in each sample 
and the relative mean fluorescence intensity of cells was determined 
on a linear scale. 
sI~Selectin ELISA.  The sandwich ELISA used to quantitate sL- 
selectin  levels in culture supernatant fluid and cell lysates was as 
described (29). Briefly, wells of 96-well microtiter plates were coated 
with the anti-LAM1-5 mAb, blocked, and the test samples were 
added to triplicate wells. After washing, the plates were incubated 
with biotinylated anti-LAM1-3 mAb, followed by avidin-horseradish 
peroxidase and finally developed. The OD of the reaction mixture 
was quantitated  using an ELISA reader.  Each assay included the 
titration of a previously quantified plasma sample that was used 
to generate a standard curve. The relative concentration of sbselectin 
in individual samples was calculated by comparing the mean OD 
obtained from triplicate  wells to a semilog standard curve of titrated 
plasma using linear regression analysis. 
Frozen Section HEV-binding Assays.  Rat lymph nodes were ob- 
tained from freshly killed Lewis rats, snap-frozen in isopentane/liquid 
nitrogen, and stored at  -70~  in isopentane until use. The HEV 
assay was as described (47). Each cell type (5  x  106 cells) was in- 
cubated on three 12-gm sections/slide  at 64 rpm for 25 min at 4~ 
The excess cells were gently removed, and the slides were placed 
vertically in ice-cold fixative (2.4%  glutaraldehyde in PBS) over- 
night.  The slides were then counterstained with Gill's hematox- 
ylin, overlaid with glycerol gelatin,  and coverslips  were applied. 
Each slide was scored for the number of test cells bound/HEV and 
100-200  HEV were counted for each experiment. 
Results 
Construction and Expression of  Selectin Chimeras and L-Selectin 
Mutants.  The chimeric P4L receptor was generated with the 
lectin, EGF, and SCR domains of P-selectin attached to the 
transmembrane (including membrane-proximal region) and 
cytoplasmic domains of L-selectin (Fig. 2 A). L4P is a similar 
domain  swap  mutant  except  the  extracellular  domain  of 
L-selectin is attached to the transmembrane and cytoplasmic 
domains of P-selectin. A cytoplasmic tail deletion mutant of 
L-selectin (LAcyto) was also generated by introducing a stop 
codon at amino acid position G 324 in the cytoplasmic domain 
(Figs.  1 and 2 A)  as described  (43).  Site-specific mutations 
and deletions within  the membrane-proximal region of the 
Table  1.  Cell-surface  Expression of Chimeric and Mutant 
L-Selectin Receptors 
mAb Reactivity 
(Mean linear fluorescence channel number) 
Receptor  Control  LAMI-1  LAM1-3  LAM1-14  AC1.2 
L-selectin  0.2  3.5  11.0  3.5  -- 
LAcyto  0.4  2.1  10.7  1.9  - 
P4L  0.4  -  -  -  1.0 
L4P  0.4  1.6  2.5  1.1  - 
KLD.KE  0.3  1.5  3.9  1.0  -- 
K283A  0.2  0.2  0.2  0.2  - 
SFS.KE  0.3  4.5  10.7  5.7  - 
MIKE  0.3  0.8  2.2  0.6  - 
KE  0.3  2.0  5.6  1.8  - 
KEGDYN  0.3  1.2  2.4  1.1  -- 
AK283  0.2  11.3  19.3  10.7  - 
K283E  0.3  4.6  9.0  5.6  -- 
K283P  0.2  3.9  8.1  4.3  -- 
AK-S  0.2  6.7  17.9  7.6  - 
AM-N  0.4  12.2  30.5  12.3  - 
AAAG  0.4  13.0  18.0  4.1  - 
All results shown are for cDNA-transfected  300.19 cells, except P4L which 
is expressed in CHO cells. Background staining levels for untransfected 
300.19 cells and CHO cells were '~0.3 fluorescence channel units. Simi- 
lar results were obtained in at least three experiments. 
transmembrane domain of L-selectin were also generated (Fig. 
2  B)  using  PCR-based  mutagenesis  protocols. 
The chimeric and mutant cDNA were used for stable trans- 
fection of an L-selectin deficient mouse pre-B cell line, 300.19, 
and for transient transfection of COS cells. Cell-surface ex- 
pression of the chimeric selectins and L-selectin mutants by 
300.19 cells or COS cells was assessed by either indirect im- 
munofluorescence staining using L- or P-selectin-specific mAb 
with flow cytometry or by immunoperoxidase staining, respec- 
tively. COS cells transiently expressed each of the receptors 
on the cell surface at high levels, while receptor expression 
by  different  300.19  clones  varied  from  low  to  high  as  is 
common for stable cDNA-transfected  cells (Tables 1 and 2, 
Fig. 3). P4L was not expressed at high levels by 300.19 cells, 
so stably transfected  CHO  cells and transiently  transfected 
COS cells expressing this receptor were studied.  CHO cells 
transfected with L- or P-selectin behaved similarly to 300.19 
and  COS  cells  transfected  with  these  receptors  (data  not 
shown)  so there is no reason to suspect that results for P4L 
from CHO cells differ from results obtained in other cell types. 
The K283A mutant receptor was not expressed at detectable 
levels on the cell surface of either 300.19 cells or COS cells, 
but was expressed at high levels intracellularly (Tables 3 and 
4, data not shown). Other mutations, such as AM-N, resulted 
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after PMA Exposure 
Mean linear fluorescence channel number 
Percent 
Receptor  Control  -  PMA  + PMA  shed* 
L-selectin  0.46  12.75  1.84  89 
LAcyto  0.43  11.30  1.15  93 
P4L  0.41  0.94  0.48  87 
L4P  0.44  2.64  4.86  --* 
KLD.KE  0.42  3.84  1.13  79 
K283A  0.21  0.21  0.21  --~ 
SFS.KE  0.44  5.49  2.06  68 
MIKE  0.44  2.30  0.56  93 
KE  0.45  5.99  0.68  96 
KEGDYN  0.43  2.27  0.57  92 
AK283  0.26  32.95  25.20  24 
K283E  0.36  23.40  16.45  30 
K283P  0.26  8.75  7.30  17 
AK-S  0.41  35.40  34.55  2 
AM-N  0.34  64.05  63.20  1 
AAAG  0.38  18.05  16.60  8 
* Percent shed = 10011  - MF( + PMA)/MF( - PMA)] with control lev- 
els subtracted from mean fluorescence  channel numbers before  the calcu- 
lations. All values represent the means observed from duplicative cell 
samples. Similar results were obtained in at least three experiments. 
Percent shed for L4P could not be calculated since surface  expression 
increased with PMA stimulation and K283A was not detectable  on the 
cell surface. 
in significantly higher levels of L-selectin being expressed on 
the cell surface in both 300.19 cells and COS cells. In all cases, 
cultured cells were examined when grown at low density, 
since high density cultures have a tendency to shed L-selectin 
at an increased rate (7). 
Structural and FunctionaI Integrity of  L-Selectin Mutants.  The 
structural integrity of the chimeric selectin and L-selectin mu- 
tant proteins was examined by analysis with mAbs specific 
for epitopes located within the lectin, EGF, and SCK do- 
mains (42). The LAM1-3 (lectin), LAMI-1 (EGF), and LAM1-4 
(SCR) mAb all bound to each of the transfected cells with 
similar relative fluorescence intensities when compared with 
wild-type L-selectin as determined by flow cytometry anal- 
ysis (Table 1). Expression of P4L was assessed using the AC1.2 
mAb specific for P-selectin SCK domains (48). Analysis with 
these mAbs demonstrate that the overall structure of the chi- 
meric and mutant receptors was not dramatically altered by 
changes in membrane-proximal domains or residues. 
The functional activity of receptors with changes in the 
membrane-proximal region was  examined by determining 
whether replacement of the entire membrane-proximal re- 
gion with four amino acids, AAAG, affected L-selectin func- 
tion. 300.19 cells expressing the AAAG mutant receptor bound 
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Figure 3.  Cell-surface  expression  of selected  chimeric  and mutant L-selec- 
tin molecules  before  and after culture with PMA. Solid histograms indi- 
cate the fluorescence  intensity of cells stained with saturating amounts 
of the anti-LAM1-3 mAb and assessed by flow cytometry;  dashed lines 
indicate staining after PMA treatment; dotted histograms indicate  back- 
ground staining with an unreactive  control mAb. 
to rat peripheral lymph node HEV (6.3  _+  3.6 cells bound/ 
HEV) as well as wild-type L-selectin-transfected cells (5.1  + 
0.7), while untransfected 300.I9 cells did not bind (0.6  _+ 
0.1). That the membrane-proximal region of L-selectin was 
not required for cell adhesion suggests that other modifica- 
tions within this region should not inhibit receptor func- 
tion.  As  previously reported,  the  L4P  and  P4L  chimeric 
receptors and LAcyto each retain the appropriate carbohy- 
drate/ligand-binding  specificities  (42, 43,  45). 
The L-Selectin Transmembrane Domain Is Required for Endo- 
proteolytic Release.  The region of L-sdectin necessary for en- 
doproteolytic release was determined using cells transfected 
with chimeric selectins (Fig. 2 A). Receptor endoproteolytic 
release was assessed by ceU-surface  immunofluorescence staining 
with flow cytometry analysis after PMA (50 ng/ml) exposure 
for 30 min at 37~  (Fig. 3, Table 2), by ELISA to quantitate 
the amount of receptor released into the culture supernatant 
fluid after PMA exposure (Table 3) and spontaneously released 
into the supernatant fluid during culture (Table 4). Quanti- 
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Release of Receptor by ELISA 
Quantity of L-selectin (total ng)* 
Receptor  Cell lysate  Supernatant  Supernatant  Ratio* 
- PMA  - PMA  + PMA 
L-selectin  37.8  3.4  22.8  0.55 
LAcyto  12.6  1.3  8.5  0.61 
L4P  13.2  <0.4  <0.4  <0.03 
KLD.KE  6.2  3.4  4.4  0.46 
K283A  9.3  3.1  5.0  0.40 
SFS.KE  8.5  3.4  5.2  0.43 
MIKE  3.8  1.0  3.0  0.63 
KE  8.8  2.8  7.0  0.60 
KEGDYN  7.9  2.7  6.6  0.63 
AK283  35.6  1.6  1.8  0.05 
K283E  17.6  1.3  1.9  0.10 
K283P  14.0  1.4  1.6  0.10 
AK-S  60.4  <0.4  <0.4  <0.01 
AM-N  86.8  <0.4  <0.4  <0.01 
AAAG  30.5  <0.4  <0.4  <0.01 
* Cells (~2  x  106) were cultured in 0.4 ml of medium containing 50 
ng/ml PMA at 37~  for 30 min. After centrifugation, the cell pellet 
was resuspended  in 0.4 ml of lysis buffer. The total quantity of L-selectin 
present in the supernatant fluid and cell lysate  was determined  by ELISA. 
* Ratio = sL-selectin/(total  L-selectin) = Sup(  + PMA)/[Lysate(  - PMA) 
+  Sup  (-PMA)].  Similar results were obtained in  at  least three 
experiments. 
tation of cell-associated L-selectin was  also  carried out by 
ELISA analysis  of detergent-solubilized cells  (Tables 3  and 
4).  This multiparameter analysis  allowed determination of 
the relative amount of receptor shed independent of the levels 
of cell-surface receptor expressed by the different cDNA- 
transfected clones. 
PMA-induced endoproteolytic  release of  L-selectin by 300.19 
ceils  transfected with  wild-type L-selectin resulted  in  an 
,o90% loss of cell-surface L-selectin expression (Fig. 3, Table 
2).  Concomitant with this,  there was  a sevenfold increase 
in the levels of sL-selectin found in the supernatant fluid of 
cells cultured in the presence of PMA (Table 3). Also, one- 
third of L-selectin generated by cells cultured for 24 h was 
found in the supernatant fluid as spontaneously shed receptor 
(Table 4).  Endoproteolytic release of LAcyto and the P4L 
receptor was similar to that of wild-type L-selectin, with an 
",~90% loss  of cell-surface receptor after PMA stimulation 
(Tables 2-4). In contrast, ceU-surface expression of L4P in- 
creased approximately twofold after PMA treatment (Fig. 3, 
Table 2), presumably because cell activation results in mobili- 
zation of P-selectin to the plasma membrane from intracel- 
lular storage granules (49).  Identical results were obtained 
using P-selectin-transfected 300.19 cells and COS cells (data 
Table  4.  Spontaneous Endoproteolytic Release of Receptors 
during 24-h  Cultures 
Quantity of L-selectin (rig)* 
Receptor  Supernatant  fluid  Cell Lysate  Sup/Lysate 
L-selectin  27.0  54.4  0.5 
LAcyto  31.5  34.0  0.9 
L4P  <1.5  12.4  <0.1 
KLD.KE  13.8  7.5  1.8 
K283A  10.7  6.9  1.5 
SFS.KE  11.0  8.1  1.4 
MIKE  12.8  8.4  1.5 
KE  5.0  4.6  1.1 
KEGDYN  13.8  13.2  1.1 
AK283  9.7  30.0  0.3 
K283E  5.7  14.5  0.4 
K283P  13.7  13.8  1.0 
AK-S  <1.5  37.5  <0.04 
AM-N  <1.5  68.0  <0.02 
AAAG  <1.5  20.1  <(0.07 
* Cells (~2  x  106)  were washed, resuspended  in 10 ml of culture medi- 
um, and cultured for 24 h. Cells from 1.5-ml aliquots of the cultures 
were harvested, pelleted, and resuspended  in 0.5 ml of lysis buffer. The 
total quantity  of L-selectin  present  in the supernatant fluid  and cell  lysate 
was determined  by ELISA. Similar  results were obtained  in at least three 
experiments. 
not shown).  L4P was not shed from the cell surface since 
it was not detected in the supernatant fluid of transfected 
cells cultured with PMA or cells cultured for 24 h  (Tables 
and 3 and 4). In all cases, similar results were obtained with 
mutant receptors transiently transfected into COS cells (data 
not shown). Collectively, these results indicate that the ex- 
traceUular lectin, EGF, and SCP, domains, and the cytoplasmic 
domain of L-selectin are not required for regulation of L-selec- 
tin endoproteolytic release. Therefore, the exon encoding the 
transmembrane domain must  encode the sites  of cleavage 
and/or regulatory elements that  promote endoproteolytic 
cleavage. 
Role of the Membrane-proximal  Sequence  in Endoproteolytic 
Release.  The role of the primary structure of the transmem- 
brane domain in L-selectin endoproteolytic release was ex- 
amined by systematically substituting each amino acid in the 
membrane-proximal region with alanine residues (Fig. 2 B). 
Essentially, these mutations generated three sets of results. 
A first group of 300.19 cells expressing L-selectin mutations 
with alanine residues substituted for KE, KEGDYN,  and 
MIKE were similar to wild-type L-selectin-transfected cells 
where >90% of the cell-surface receptor was shed after PMA 
exposure (Table 2). Similarly, a large fraction of the receptor 
was shed into the supernatant fluid (Tables 3 and 4). A second 
group of mutations in the KLD.KE or SFS.KE sequences re- 
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68%, respectively (Fig. 3, Table 2) with a small decrease in 
receptor release into the supernatant fluid after PMA exposure 
(Table 3). These subtle differences were most evident when 
the amount of PMA needed to induce optimal cell-surface 
receptor endoproteolytic release was determined. A PMA con- 
centration  of 10 ng/ml  induced >80%  endoproteolytic re- 
lease  of L-selectin and KE,  KEGDYN,  or MIKE mutants 
(Fig.  4, and data not shown), while a PMA concentration 
of 50 ng/ml  was required  to induce maximal  endoproteo- 
lyric release  of SFS.KE and KLD.KE mutants  (Fig.  4). 
The third  type of result was obtained with  the K283A 
mutant  receptor which changed a basic residue within the 
putative cleavage site to a neutral residue. This mutant receptor 
was not expressed at detectable levels on the cell surface (Tables 
I and 2), but was released into the supernatant fluid at levels 
comparable to L-selectin (Tables 3 and 4). Since this receptor 
was expressed within the cytoplasm of the transfected cells 
(Tables 3 and 4), it is likely that the receptor is immediately 
cleaved after expression on the cell surface. Nonetheless, high 
levels of sL-selectin accumulated in the culture supernatant 
fluid for all alanine substitution mutants examined (Table 4). 
Similar  results  to  those  described  above for  each  mutant 
receptor were also obtained with transiently transfected COS 
cells (data not shown).  These results suggest that receptor 
endoproteolytic release is independent of the specific sequence 
MIKEGDYN within the membrane-proximal region of the 
transmembrane domain, whereas residues within the sequence 
KLDKSFS are more critical,  although not absolutely required, 
for regulation  of receptor endoproteolytic release. 
Endoproteolytic Release Requires a  Unique Structure of the 
Cleavage Site.  Since the K283A mutation  resulted in un- 
regulated endoproteolytic release  of L-selectin,  the limit of 
tolerance for amino  acid substitutions at this location was 
examined.  Deletion  of K 2s3  (AK283)  resulted  in  a  73% 
reduction in cell-surface receptor endoproteolytic release in 
30-min cultures containing PMA (Table 2). Changing K 2s3 
to an acidic glutamic acid residue (K293E) also reduced en- 
doproteolytic release by ~70%  (Fig. 3, Table 2).  Similarly, 
changing  K 2s3 to proline (K283P), a residue that is known 
to induce profound local conformational changes in proteins, 
reduced release by ~80%. Consistently, less receptor was shed 
into the culture medium from AK283-, K283P-, and K283E- 
transfected cells than from wild-type L-selectin-transfected 
cells during 30-rain cultures stimulated with PMA (Table 3). 
These mutations also reduced the sensitivity of L-selectin to 
PMA-induced endoproteolytic release  since even high con- 
centrations  of PMA caused only low level endoproteolytic 
release of these receptors (Fig.  4). However, in 24-h cell cul- 
tures not containing  PMA, the relative amount  of soluble 
AK283 and K283E receptor was not much less than that of 
wild-type L-selectin, while the K293P mutant was sponta- 
neously shed to a high level,  similar to the alanine-scanning 
mutants (Table 4). Collectively, these data suggest that the 
kinetics of receptor cleavage are delayed by these mutations, 
but that high concentrations of spontaneously shed receptor 
can accumulate in culture supernatant fluid over 24 h despite 
cleavage at a slower rate. Alternatively, spontaneous cleavage 
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Figure 4.  Dose  dependence of PMA-induced endoproteolytic release 
of I, selectin. Cells were cultured with or without PMA for 30 min. The 
percentage of cell surface L-selectin that was lost was determined as in 
Table 2. 
could result from mechanisms distinct from those that  are 
PMA-induced. Nonetheless, these results and the results ob- 
tained with the alanine-scanning  mutations,  suggest that  a 
unique local structure rather  than sequence at the cleavage 
site needs to be preserved for L-selectin to be optimally rec- 
ognized  and/or  cleaved by the endoprotease. 
Length of the Membrane-proximal  Region Is Critical.  Since 
proteolytic cleavage does not require a specific sequence within 
the membrane-proximal region of L-selectin, the distance of 
the cleavage  site from the cell membrane could also affect 
endoproteolytic release.  To test this possibility, the amino- 
or carboxy-terminal half of the membrane-proximal  region 
of L-selectin was deleted (Fig.  2 B). The resulting mutants, 
AK-S and AM-N, were not shed from the cell surface of trans- 
fected 300.19 cells (Fig. 3, Table 2) and sL-selectin was not 
detectable in the supernatant  fluid of PMA-stimulated cells 
(Table  3) or 24-h cultured cells  (Table 4).  Similarly,  when 
the membrane-proximal region was eliminated and replaced 
with AAAG (Fig. 2 B), L-selectin was not released from the 
cell surface of transfected 300.19 cells (Tables 2-4) regardless 
of the level of PMA used to stimulate endoproteolytic cleavage 
(Fig.  4). Thus,  even though the putative protease recogni- 
tion motif was present in the AM-N mutant receptor, a cer- 
tain length  of the membrane-proximal  region  (at least >8 
amino acids long) was absolutely essential for endoproteo- 
lytic release of the receptor.  Identical results were obtained 
with transiently transfected COS cells in each case (data not 
shown). 
Discussion 
Mutagenesis experiments carried out in this study are con- 
sistent with release of L-selectin from the cell surface through 
a proteolytic mechanism. Chimeric P- and L-selectin receptors, 
in conjunction with an L-selectin cytoplasmic domain trun- cation mutant (Fig. 2), localized cleavage sites between Q279 
and G 323 (Fig. 1). The L4P chimera contained the entire ex- 
tracellular domain of L-selectin except the transmembrane 
and cytoplasmic domains, but was not shed at detectable levels 
(Fig. 3, Tables 2-4). In contrast, the reciprocal receptor P4L 
was shed (Tables 2-4). Although the P4L chimeric receptor 
contained a portion of the last SCR of L-selectin, this region 
is not a potential site for endoproteolytic release since the 
receptor  would  remain  membrane  attached  through  the 
disulfide bond of Cys  27s at the end of the SCR.  Although 
the cytoplasmic domain of L-selectin is critical for receptor 
function (43), it is unlikely to regulate receptor cleavage since 
deletion of the entire cytoplasmic domain (LAcyto) failed to 
affect endoproteolytic release (Tables 2-4).  Thus, all of the 
structural elements that regulate endoproteolytic release of 
L-selectin appear to be contained within the transmembrane 
domain. Although a role for the membrane-spanning por- 
tion of L-selectin in regulation of endoproteolytic release was 
not revealed by these studies, it is likely that it is involved 
in some aspect of receptor function since there has been com- 
plete conservation within this region during recent mam- 
malian evolution (Fig.  1). 
Sites of L-selectin cleavage are likely to reside within the 
amino-terminal portion of the transmembrane domain. De- 
letion of K 2s3, or changing K 2s3 to glutamate or proline, dra- 
matically reduced the kinetics of PMA-induced endoproteo- 
lytic release by 70-80%, confirming that amino acid 283 is 
likely to be at or near the primary receptor cleavage site (Fig. 
3 and 4, Tables 2 and 3). However, changing K 2s3 to gluta- 
mate or proline did not significantly inhibit the amount of 
sL-selectin that accumulates in the supernatant fluid of cul- 
tured cells (Table 4). Substitution of K 283 with a neutral res- 
idue  dramatically increased  the  level  of spontaneous  en- 
doproteolytic release (Tables 2-4). Substitution of amino acids 
proximal to the putative primary cleavage site, KLD  2s2, and 
SFS  TM reduced PMA-induced endoproteolytic release by 20- 
30% (Table 2, Fig. 4), with considerable endoproteolytic re- 
lease of the receptor into the supernatant fluid of cultured 
cells (Tables 3 and 4).  Mutations within the MIKEGDYN 
amino acid sequence, more than three residues away from 
the putative  K 283 cleavage site,  did  not  have  a  detectable 
effect on endoproteolytic release (Fig. 3, Tables 2-4). There- 
fore, while K 283 appears important for receptor shedding, the 
K 2s3 SFS motif or residues near this amino acid motif were 
not required for endoproteolytic release.  This is consistent 
with the lack of the KSFS motif in bovine L-selectin which 
is  nonetheless shed from the cell surface (39).  Therefore, 
cleavage of L-selectin appears to be mediated by an endoprotease 
with relaxed sequence specificity. 
Although cleavage of L-selectin did not require a specific 
primary amino acid sequence, this study suggests that two 
related factors contribute to protease susceptibility. First, a 
particular structure that can be generated by a series of se- 
quences within the cleavage site appears  essential.  Substitu- 
tion of K 283 with glutamate or proline sufficiently altered 
the secondary or tertiary structure of this region so that it 
greatly reduced the kinetics of endoproteolytic release. Simi- 
larly, but with opposite effects, changes resulting from the 
K283A mutation made the receptor immediately susceptible 
to spontaneous cleavage such that it was not detectable on 
the cell surface,  while it was found at normal levels in the 
cytoplasm and supernatant fluid. A second and directly related 
constraint is that the cleavage site must be at a certain dis- 
tance from the plasma membrane. The mutant AM-N receptor 
was not shed, possibly because its unaltered deavage site was 
too proximal to the membrane. This suggests that in addi- 
tion to conformational constraints, the active site of the en- 
doprotease may be restricted to a certain distance above the 
membrane. Therefore, the most likely explanation for why 
L-selectin is endoproteolyticaUy released from the cell sur- 
face at a high rate while P- and E-selectin are not is likely 
to be a combination of sequence and length constraints on 
tertiary structure within the membrane-proximal regions of 
these receptors. 
The amino acid substitutions examined in this study could 
affect L-selectin proteolytis in at least two indirect ways. First, 
primary structural changes could produce cleavage sites rec- 
ognized by proteases not normally involved in L-selectin en- 
doproteolytic release. This is not likely as the primary site 
for proteolytic cleavage suggested in this study using a muta- 
tional approach is in agreement with that obtained by others 
using radiochemical sequencing (31). Second, primary struc- 
tural changes could provide better, or worse, substrates of 
normal or ectopic endoproteases, which would alter the rates 
of L-selectin cleavage. Undoubtedly this occurs as was dra- 
matically revealed by the K283A mutant receptor. However, 
receptor cleavage was examined in a number of ways to con- 
trol for these influences. First, receptor shedding from the 
cell surface was assessed after brief PMA activation of the 
cells which specifically augments release of this receptor (Figs. 
3 and 4, and Tables 2 and 3). Second, accumulation of receptor 
in the supernatant fluid as well as that retained in the cell 
was assessed after brief PMA exposure (Fig. 3, Table 3). Third, 
spontaneous accumulation of shed receptor in the superna- 
tant fluid was assessed after culture of transfected cells for 
24 h to assesses receptor shedding in the event that the ki- 
netics of shedding were inhibited (Table 4). Fourth, the dose 
response  of cells  to  various  concentrations of PMA  was 
assessed to determine the relative susceptibility of mutant 
receptors to activation-induced shedding. Therefore, although 
primary structural changes in L-selectin appeared to alter the 
secondary and high order conformation of the receptor and 
also altered the kinetics of endoprotease-mediated cleavage, 
the results with each of these assay systems were consistent, 
further strengthening the validity of the conclusions for the 
primary L-selectin cleavage site. 
Cleavage of L-selectin is most likely due to a membrane- 
bound protease with an extracellular catalytic domain con- 
stitutively  present  on  the  membrane  (9).  Further,  this 
endoprotease activity must be widely distributed since iden- 
tical results were obtained in this study with mutant receptors 
transfected into a mouse pre--B cell line, monkey kidney fibro- 
blasts  (COS cells), and CHO cells. Similar results have also 
been obtained with radiochemical sequencing of L-selectin 
released from COS cells and human lymphocytes (31). Since 
endoproteolytic release of L-selectin is increased rapidly in 
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stimulation may activate endoproteases already present within 
the membrane and thereby enhance proteolytic activity. The 
existence of widely distributed, PMA-sensitive endoproteo- 
lytic pathways has been suggested for the cleavage of trans- 
forming growth factor receptor (50),  macrophage colony- 
stimulating factor receptor (4),  LAR (51),  and 3  amyloid 
protein (13). Alternatively for L-selectin, cellular activation or 
ligand binding may induce conformational changes in the 
membrane-proximal region of the receptor that expose na- 
scent sites which are highly susceptible to enzymatic cleavage. 
This is supported by the immediate endoproteolytic release 
of the K283A mutant receptor from the cell surface without 
cellular stimulation. Ligand binding or cell activation may 
direct  the membrane-proximal region of L-selectin into a 
protease-susceptible conformation similar to that induced by 
the K283A mutation. This is likely to be physiologically rele- 
vant since cellular activation up-regulates the affinity of L-selec- 
tin for ligand through conformational changes in receptor 
structure or organization within the membrane (52).  This 
process would allow for a rapid increase in receptor affinity 
that would then be rapidly down-modulated through receptor 
release from the cell surface. 
The failure to completely eliminate shedding by changing 
K 283 to glutamate or proline could be explained solely by 
primary structural changes that alter the conformation of the 
receptor and thereby only inhibit the kinetics of endoproteol- 
ysis. However, a second explanation for these data is that the 
K 283 recognition region is the primary but not the sole en- 
doprotease cleavage site and that these changes thereby reveal 
additional normal and/or unusual cleavage sites. In this case, 
mutations of K 283 may abolish endoproteolytic release at that 
site, but cleavage at a secondary and perhaps less efficient site 
could still occur. This may be likely since our analysis of the 
primary data published in the study that identified a sin- 
gle putative cleavage  site for L-selectin after K 283 suggests a 
potential secondary cleavage site for the receptor within the 
membrane-proximal region (31).  Our analysis of their pub- 
lished radiochemical sequencing data finds a minor [35S]me- 
thionine peak at cycle 14 and two minor [3H]pbenylalanine 
peaks at cycle positions 8 and 18. These results suggest receptor 
cleavage at a secondary site after K 2s9 (Fig.  1). Again,  the 
amino acid sequence surrounding this potential cleavage site 
is not conserved in bovine L-selectin (39) and changes in this 
sequence do not affect L-selectin shedding (Tables 2-4). That 
additional minor cleavage sites exist within the membrane 
proximal region of L-selectin cannot be ruled out, but all 
of the results obtained in this study are consistent with a 
primary cleavage site within the amino-terminal portion of 
the membrane-proximal region and a potential  secondary 
cleavage site within the carboxy-terminal portion of the mem- 
brahe-proximal region. In both cases, the enzyme or enzymes 
that mediate endoproteolytic release of L-selectin from the 
cell surface appear flexible in their sequence specificity and 
were up-regulated after PMA activation of receptor-expressing 
cells. Further, the structure of both cleavage sites and their 
relationship to membrane-spanning and SCR domains ap- 
pears critical to shedding as the AK-S receptor was not shed 
from the cell surface even though the region containing K 29s 
remained intact. 
The molecular basis of receptor endoproteolytic release has 
only been examined in a small number of cases (1, 2). The 
best studied example of receptor endoproteolytic release is 
3  amyloid precursor protein, which as been directly impli- 
cated in the genesis of Alzheimer's disease (13).  Cleavage of 
3-amyloid precursor protein is through unidentified enzymes 
designated oe- and 3-secretase  that  cleave  at different sites 
within the protein (13). Cleavage of ~-amyloid precursor pro- 
tein by oe-secretase is remarkably similar to what has been 
observed with L-selectin. First, cleavage of 3-amyloid precursor 
protein is a physiologic process observed in all cell lines that 
express this protein and in cDNA-transfected cells (53-55). 
Second, as with L-selectin, an array ofprotease inhibitors has 
failed to inhibit ~-amyloid precursor protein cleavage from 
intact cells (11, 56-58).  Third, 3-amyloid precursor protein 
cleavage is accelerated in response to cell activation or PMA 
stimulation (59). Fourth, both proteins are primarily cleaved 
at a peptide bond after a lysine residue '~12 amino adds above 
the membrane. There is little sequence specificity for oe, seere- 
tase cleavage since most  amino acids  substitutions  in the 
cleavage site do not affect receptor proteolysis (53-55). How- 
ever, substitutions with helix-destabilizing amino adds at and 
near the cleavage site inhibit endoproteolytic release (60). Fifth, 
natural mutations in critical residues of the ~-seeretase cleavage 
site actually accelerate endoproteolytic release and the acceler- 
ated development of Alzheimer's disease (61, 62). Finally, the 
shed forms of both receptors have been found in normal body 
fluids. Similar to the level of heterogeneity observed with 
the cleavage sites of L-selectin, 3-amyloid precursor protein 
cleavage generates additional minor peptide species due to 
endoproteolytic cleavage at sites in addition to the predomi- 
nant cleavage site (13). Therefore, it is possible that oe-secretase 
is  a  ubiquitous  membrane  endoprotease  that  also  cleaves 
L-selectin and other unidentified membrane proteins. These 
observations suggest a generalized protein processing pathway 
involved in the secretion of specific integral membrane pro- 
teins that may be mediated by a common mechanism or family 
of membrane bound endoproteases that exhibit a relaxed amino 
acid sequence specificity. Identification and characterization 
of these endoproteases could therefore have broad implica- 
tions for an array of cell-surface receptor systems and ther- 
apeutic agents. 
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